Skip to main content
. Author manuscript; available in PMC: 2019 Jul 15.
Published in final edited form as: J Immunol. 2018 Jun 8;201(2):481–492. doi: 10.4049/jimmunol.1701477

Figure 5.

Figure 5

mTORC1-deficient Tregs have decreased effector molecule expression

B16-F10 melanoma cells (2 × 105) were inoculated subcutaneously in WT or T-Rptor−/− mice. (a) Tumor area and mass of B16-F10 tumors were measured at day 14 post-inoculation. (b) Percentage of tumor infiltrating Tregs between WT and T-Rptor−/− mice was examined. Summary is shown on the right. (c–e) Summary of flow cytometry analysis of effector molecules (c) ICOS, (d) CTLA-4, and (e) PD-1 between WT and T-Rptor−/− Tregs in tumors was examined. (f) Sorted splenic WT or T-Rptor−/− eTregs were combined with conventional CD4+ and CD8+ T cells and then adoptively transferred to Rag2−/− mice. Two days post cell transfer, mice were implanted subcutaneously with B16-F10 melanoma cells. Tumor growth was monitored over time. *P < 0.05; **P < 0.005; ***P < 0.0005; ns, no significance (Mann-Whitney t test). Data are representative of at least three (a–e) or two independent experiments (f).